Want to see AXSM full AI Analyst Report?

Axsome Therapeutics (AXSM) Price & Analysis

2,393 Followers

AXSM Stock Chart & Stats

$241.00

-$0.53(-0.22%)

At close: Jul 24 4:00 PM EDT

$241.00

-$0.53(-0.22%)

Day’s Range― - ―

52-Week Range$104.15 - $260.19

Previous CloseN/A

Volume461.99K

Average Volume (3M)1.02M

Market Cap

$11.30B

Enterprise Value$12.58K

Total Cash (Recent Filing)$319.85M

Total Debt (Recent Filing)$219.21M

Price to Earnings (P/E)―

Beta0.75

Next Earnings

Nov 09, 2026

EPS Estimate

-0.47

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.75

Shares Outstanding52,380,817

10 Day Avg. Volume706,319

30 Day Avg. Volume1,019,090

Financial Highlights & Ratios

PEG Ratio1.29

Price to Book (P/B)102.90

Price to Sales (P/S)14.23

P/FCF Ratio-96.78

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$291.00

Price Target Upside20.75% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering13

EPS Forecast (FY)-2.61

Revenue Forecast (FY)$964.38M

Bulls Say, Bears Say

Bulls Say

Revenue Growth & Gross MarginAxsome has scaled U.S. product sales rapidly and generates very high product margins (~93% TTM). That structural margin profile gives durable operating leverage: as commercial scale continues, high gross profitability can fund R&D and commercialization and accelerate the path to sustained operating profitability.

AUVELITY Alzheimer's ApprovalThe new AUVELITY approval for agitation in Alzheimer's is a first‑in‑class, high‑unmet‑need indication that expands addressable market and extends product lifecycle. Durable regulatory labeling with payer uptake supports long‑term prescription volume and revenue diversification beyond MDD.

Deep Late‑stage CNS PipelineA broad, late‑stage CNS portfolio (six candidates, an AXS‑12 NDA and multiple upcoming Phase III programs) provides multi‑year optionality. Successful approvals would create new revenue streams, reduce single‑product concentration risk and sustain growth even if individual trials face delays.

Bears Say

Negative Operating & Free Cash FlowAxsome remains cash‑consumptive with negative operating and free cash flow (TTM ~ -$71M). Although cash burn has narrowed, persistent negative FCF forces reliance on financing until margins or revenue convert to sustained positive cash generation, limiting strategic flexibility and increasing dilution/refinancing risk.

High Leverage / Thin EquitySignificant leverage (debt ~$219M, debt/equity ~2.63) and relatively thin equity amplify financial risk. High leverage raises interest and refinancing exposure, constrains the company's ability to fund M&A or additional spend, and magnifies downside for shareholders until consistent profitability rebuilds equity cushions.

High Gross-to-net & Rising SG&AMaterial gross‑to‑net discounts (low‑mid 50% for AUVELITY/SUNOSI; high‑70% for SYMBRAVO) directly reduce realized revenue and margins. Combined with a substantial SG&A increase to $185M for sales force expansion and DTC, these structural cost and pricing pressures delay conversion of top‑line growth into sustainable operating profits.

Axsome Therapeutics News

Axsome Therapeutics price target lowered to $297 from $304 at RBC Capital

RBC Capital analyst Leonid Timashev lowered the firm’s price target on Axsome Therapeutics (AXSM) to $297 from $304...

2d ago

AXSM

Axsome Therapeutics price target raised to $251 from $242 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Axsome Therapeutics (AXSM) to $251 from $242 and keeps an...

2d ago

AXSM

Axsome Therapeutics price target raised to $275 from $260 at Guggenheim

Guggenheim raised the firm’s price target on Axsome Therapeutics (AXSM) to $275 from $260 and keeps a Buy...

2d ago

AXSM

Axsome Therapeutics price target raised to $256 from $255 at Wells Fargo

Wells Fargo raised the firm’s price target on Axsome Therapeutics (AXSM) to $256 from $255 and keeps an...

2d ago

AXSM

Axsome Therapeutics reports Q2 EPS (99c), consensus (85c)

Reports Q2 revenue $218.38M, consensus $221.78M. “The second quarter was highly productive for Axsome. Our commercial business grew...

3d ago

AXSM

These Are the Stocks Reporting Earnings Today – August 10, 2026

Here’s a look at today’s key earnings reports from major publicly traded companies. Stock market investors will undoubtedly...

3d ago

DJT

Axsome Therapeutics price target lowered to $306 from $310 at Mizuho

Mizuho lowered the firm’s price target on Axsome Therapeutics (AXSM) to $306 from $310 and keeps an Outperform...

13d ago

AXSM

Shopify downgraded, Five Below upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

23d ago

Axsome Therapeutics initiated with an Outperform at BMO Capital

BMO Capital analyst Malcolm Hoffman initiated coverage of Axsome Therapeutics (AXSM) with an Outperform rating and $310 price...

24d ago

AXSM

Axsome Therapeutics initiated with an Outperform at BMO Capital

BMO Capital initiated coverage of Axsome Therapeutics (AXSM) with an Outperform rating and $310 price target Published first...

24d ago

AXSM

Axsome Therapeutics announces FDA acceptance of AXS-12 NDA

Axsome Therapeutics (AXSM) announced that the FDA has accepted for filing the company’s new drug application for AXS-12...

29d ago

AXSM

Analyst Reiterates Buy on Axsome, Sees Undervalued Pipeline Upside with Unchanged $310 Price Target

Malcolm Hoffman, an analyst from BMO Capital, maintained the Buy rating on Axsome Therapeutics. The associated price target...

2d ago

AXSM

Auvelity Momentum and Pipeline Progress Drive Undervalued Upside in Axsome, Supporting Buy Rating

Bank of America Securities analyst Jason Gerberry has reiterated their bullish stance on AXSM stock, giving a Buy...

2d ago

AXSM

Myles Minter Reiterates Buy on Axsome as Auvelity Outperformance and AXS-12 NDA Acceptance Strengthen Long-Term Growth Outlook

William Blair analyst Myles Minter has maintained their bullish stance on AXSM stock, giving a Buy rating today....

3d ago

AXSM

AXSM FAQ

What was Axsome Therapeutics Inc’s price range in the past 12 months?

Axsome Therapeutics Inc lowest stock price was $104.15 and its highest was $260.19 in the past 12 months.

What is Axsome Therapeutics Inc’s market cap?

Axsome Therapeutics Inc’s market cap is $11.30B.

When is Axsome Therapeutics Inc’s upcoming earnings report date?

Axsome Therapeutics Inc’s upcoming earnings report date is Nov 09, 2026 which is in 88 days.

How were Axsome Therapeutics Inc’s earnings last quarter?

Axsome Therapeutics Inc released its earnings results on Aug 10, 2026. The company reported -$0.99 earnings per share for the quarter, missing the consensus estimate of -$0.892 by -$0.098.

Is Axsome Therapeutics Inc overvalued?

According to Wall Street analysts Axsome Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Axsome Therapeutics Inc pay dividends?

Axsome Therapeutics Inc does not currently pay dividends.

What is Axsome Therapeutics Inc’s EPS estimate?

Axsome Therapeutics Inc’s EPS estimate is -0.47.

How many shares outstanding does Axsome Therapeutics Inc have?

Axsome Therapeutics Inc has 52,380,817 shares outstanding.

What happened to Axsome Therapeutics Inc’s price movement after its last earnings report?

Axsome Therapeutics Inc reported an EPS of -$0.99 in its last earnings report, missing expectations of -$0.892. Following the earnings report the stock price went up 3.831%.

Which hedge fund is a major shareholder of Axsome Therapeutics Inc?

Currently, no hedge funds are holding shares in AXSM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Axsome Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

19.02%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Axsome Therapeutics Inc

Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.

Axsome Therapeutics (AXSM) Earnings & Revenues

Historic Earnings Reports

AXSM Company Deck

AXSM Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call conveys strong commercial momentum and multiple material positive milestones: 57% YoY revenue growth, AUVELITY's new FDA approval and upgraded $8B peak-sales outlook, sales-force expansions, meaningful payer wins, and an advancing late-stage pipeline with recent BD adding AXS-20. Offsetting risks include materially higher SG&A, elevated gross-to-net discounts (notably for SYMBRAVO), a modest widening of net loss, a slight decline in cash, and remaining clinical/regulatory uncertainties for several pipeline assets. On balance, the positives (robust revenue growth, regulatory wins, and clear commercial execution) significantly outweigh the near-term financial and access headwinds.View all AXSM earnings summaries

AXSM Stock 12 Month Forecast

Average Price Target

$291.00

▲(20.75% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"102":"$102","381":"$381","171.75":"$171.8","241.5":"$241.5","311.25":"$311.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":380,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$380.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":291,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$291.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":251,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$251.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[102,171.75,241.5,311.25,381],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,217.99,230.4523076923077,242.9146153846154,255.37692307692308,267.83923076923077,280.3015384615385,292.76384615384615,305.22615384615386,317.6884615384615,330.15076923076924,342.6130769230769,355.0753846153846,367.5376923076923,{"y":380,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,217.99,223.60615384615386,229.2223076923077,234.83846153846156,240.45461538461538,246.07076923076923,251.68692307692308,257.3030769230769,262.91923076923075,268.5353846153846,274.15153846153845,279.7676923076923,285.38384615384615,{"y":291,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,217.99,220.52923076923076,223.06846153846155,225.6076923076923,228.1469230769231,230.68615384615384,233.22538461538463,235.76461538461538,238.30384615384617,240.84307692307692,243.3823076923077,245.92153846153846,248.46076923076924,{"y":251,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":103.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.47,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.57,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":134.99,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":149.03,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":182.64,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185.88,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":166.38,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":171.78,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":206.53,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":230.25,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":240.66,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":217.99,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >